MX2024008450A - Piperidinil-metil-purina aminas enriquecidas con deuterio y compuestos relacionados y su uso en el tratamiento de enfermedades y condiciones - Google Patents

Piperidinil-metil-purina aminas enriquecidas con deuterio y compuestos relacionados y su uso en el tratamiento de enfermedades y condiciones

Info

Publication number
MX2024008450A
MX2024008450A MX2024008450A MX2024008450A MX2024008450A MX 2024008450 A MX2024008450 A MX 2024008450A MX 2024008450 A MX2024008450 A MX 2024008450A MX 2024008450 A MX2024008450 A MX 2024008450A MX 2024008450 A MX2024008450 A MX 2024008450A
Authority
MX
Mexico
Prior art keywords
purine
piperidinyl
methyl
treatment
deuterium
Prior art date
Application number
MX2024008450A
Other languages
English (en)
Spanish (es)
Inventor
Terrence Joseph Connolly
Chad Arthur Lewis
Original Assignee
K36 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by K36 Therapeutics Inc filed Critical K36 Therapeutics Inc
Publication of MX2024008450A publication Critical patent/MX2024008450A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024008450A 2022-01-05 2024-07-04 Piperidinil-metil-purina aminas enriquecidas con deuterio y compuestos relacionados y su uso en el tratamiento de enfermedades y condiciones MX2024008450A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263296676P 2022-01-05 2022-01-05
PCT/US2023/010204 WO2023133201A1 (en) 2022-01-05 2023-01-05 Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions

Publications (1)

Publication Number Publication Date
MX2024008450A true MX2024008450A (es) 2024-12-06

Family

ID=87074217

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008450A MX2024008450A (es) 2022-01-05 2024-07-04 Piperidinil-metil-purina aminas enriquecidas con deuterio y compuestos relacionados y su uso en el tratamiento de enfermedades y condiciones

Country Status (10)

Country Link
US (2) US12492203B2 (https=)
EP (1) EP4460502A4 (https=)
JP (1) JP2025504379A (https=)
KR (1) KR20240158230A (https=)
CN (1) CN119032094A (https=)
AU (1) AU2023205553A1 (https=)
CA (1) CA3242612A1 (https=)
IL (1) IL314062A (https=)
MX (1) MX2024008450A (https=)
WO (1) WO2023133201A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021026803A1 (en) 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
AU2023397773A1 (en) * 2022-12-12 2025-06-26 K36 Therapeutics, Inc. Pharmaceutical compositions containing a piperidinyl-methyl-purine amine and their use in treating diseases and conditions
US20250171445A1 (en) * 2023-11-17 2025-05-29 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
CN117843641B (zh) * 2023-12-28 2025-04-25 和径医药科技（上海）有限公司 Nsd3抑制剂及其制备方法和应用
WO2025259850A1 (en) * 2024-06-12 2025-12-18 K36 Therapeutics, Inc. Pharmaceutical compositions containing a deuterium-enriched piperidinyl-methyl-purine amine and their use in treating diseases and conditions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010044981A2 (en) 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
WO2021026803A1 (en) 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
US20220380371A1 (en) 2019-09-20 2022-12-01 Novartis Ag Mll1 inhibitors and anti-cancer agents
AR122159A1 (es) 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
WO2023225154A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
AU2023273656A1 (en) 2022-05-18 2024-11-28 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine d-tartaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225150A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225144A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
US20250361235A1 (en) 2022-05-23 2025-11-27 K36 Therapeutics, Inc. Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions
US20250206740A1 (en) 2022-05-23 2025-06-26 K36 Therapeutics, Inc. Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions
EP4583915A1 (en) 2022-09-09 2025-07-16 The Trustees Of Columbia University In The City Of New York Methods of treating neuroendocrine prostate cancer (nepc) by inhibiting nuclear receptor binding set domain protein 2 (nsd2)
AU2023397773A1 (en) 2022-12-12 2025-06-26 K36 Therapeutics, Inc. Pharmaceutical compositions containing a piperidinyl-methyl-purine amine and their use in treating diseases and conditions
US20250171445A1 (en) 2023-11-17 2025-05-29 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions

Also Published As

Publication number Publication date
EP4460502A1 (en) 2024-11-13
IL314062A (en) 2024-09-01
AU2023205553A1 (en) 2024-07-25
CA3242612A1 (en) 2023-07-13
US20260049083A1 (en) 2026-02-19
US20240352017A1 (en) 2024-10-24
US12492203B2 (en) 2025-12-09
EP4460502A4 (en) 2025-12-24
CN119032094A (zh) 2024-11-26
JP2025504379A (ja) 2025-02-12
WO2023133201A1 (en) 2023-07-13
KR20240158230A (ko) 2024-11-04

Similar Documents

Publication Publication Date Title
MX2024008450A (es) Piperidinil-metil-purina aminas enriquecidas con deuterio y compuestos relacionados y su uso en el tratamiento de enfermedades y condiciones
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
MX2022005256A (es) Inhibidores de cd73.
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
MX2023002507A (es) Inhibidores de cd73.
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP109934A (es) Compuesto - 946
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
CL2004000732A1 (es) Compuestos derivados de oximas sustituidas y sus sales farmaceuticamente aceptables; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los contiene; y uso de los compuestos para el tratamiento del cancer.
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900119A (es) Derivados de indolina sustitudos como inhibidores de la replicación vírica de dengue
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CY1111203T1 (el) 4-ανιλινοκινολινο-3-καρβοξαμιδια ως αναστολεις κινασης csf-1r
CR20180496A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
UY29092A1 (es) Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
EA201990949A1 (ru) Сульфоксиалкильные органические нитросоединения и родственные соединения и фармацевтические композиции для применения в медицине
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
CL2021001244A1 (es) Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos de los mismos
CO2024009144A2 (es) Inhibidores de cinasa met
CO2022016754A2 (es) Moléculas de fijación para el tratamiento de cáncer
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo